This Article Full Text (PDF) All Versions of this Article: 0009922809332683v1 48/6/609    most recent References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Scopus Google Scholar Articles by Yoon, E. Y. Articles by Clark, S. J. PubMed PubMed Citation Articles by Yoon, E. Y. Articles by Clark, S. J. Social Bookmarking                         What's this?

Formulary Coverage for Lipid-Lowering Drugs Recommended for Children

Division of General Pediatrics, University of Michigan, Ann Arbor, Michigan, est{at}med.umich.edu

Gary L. Freed, MD, MPH

Division of General Pediatrics, University of Michigan, Ann Arbor, Michigan

Matthew M. Davis, MD, MAPP

Division of General Internal Medicine and Public Policy, University of Michigan, Ann Arbor, Michigan

Sarah J. Clark, MPH

Division of General Pediatrics, University of Michigan, Ann Arbor, Michigan

Objective/methods. A cross-sectional assessment to describe availability, coverage, and pediatric labeling status of lipid-lowering drugs offered by 1 private and 1 public insurance plan formularies. Results. Both insurance plans had equal medication availability of bile acid sequestrants (7), statins (10), and cholesterol-absorption blockers (CAB; 1). The private plan had 3 bile acid sequestrants and 3 statins listed as preferred drugs; the CAB was not preferred. In contrast, the public plan had 5 bile acid sequestrants, 7 statins, and the CAB as preferred drugs. For medications with pediatric labeling, the private plan covered 50% as preferred drugs whereas the public plan covered 70% as preferred drugs. Conclusions. If new recommendations of the American Academy of Pediatrics for treatment of dyslipidemia in children were implemented today, children with the public plan would have equal choice but better coverage of lipid-lowering drugs as preferred drugs, including those with FDA approval, compared with children with the private plan.

Key Words: pediatric labeling • formulary • insurance plans • cholesterol • obesity • dyslipidemia

This version was published on July 1, 2009

Clinical Pediatrics, Vol. 48, No. 6, 609-613 (2009)
DOI: 10.1177/0009922809332683


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?